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Background: Evidence from clinical studies and preclinical animal models suggests that proinflammatory cytokine
overproduction is a potential driving force for pathology progression in traumatic brain injury (TBI). This raises the
possibility that selective targeting of the overactive cytokine response, a component of the neuroinflammation that
contributes to neuronal dysfunction, may be a useful therapeutic approach. MW151 is a CNS-penetrant, small molecule
experimental therapeutic that selectively restores injury- or disease-induced overproduction of proinflammatory
cytokines towards homeostasis. We previously reported that MW151 administered post-injury (p.i.) is efficacious in a
closed head injury (CHI) model of diffuse TBI in mice. Here we test dose dependence of MW151 to suppress the target
mechanism (proinflammatory cytokine up-regulation), and explore the therapeutic window for MW151 efficacy.
Methods: We examined suppression of the acute cytokine surge when MW151 was administered at different times
post-injury and the dose-dependence of cytokine suppression. We also tested a more prolonged treatment with
MW151 over the first 7 days post-injury and measured the effects on cognitive impairment and glial activation.
Results: MW151 administered up to 6 h post-injury suppressed the acute cytokine surge, in a dose-dependent manner.
Administration of MW151 over the first 7 days post-injury rescues the CHI-induced cognitive impairment and reduces
glial activation in the focus area of the CHI.
Conclusions: Our results identify a clinically relevant time window post-CHI during which MW151 effectively restores
cytokine production back towards normal, with a resultant attenuation of downstream cognitive impairment.
Keywords: Cytokines, Glia, Interleukin, Neuroinflammation, Drug discovery, Microglia, Astrocytes, Traumatic brain injury,
Closed head injury, Cognitive dysfunctionIntroduction
Traumatic brain injury (TBI) is a public health problem
associated with injuries sustained by military personnel,
concussion-related sports injuries, and falls in the elderly
[1]. TBI initiates a cascade of complex pathophysiological
events that can themselves add to physiological injury and
the longer-term morbidity related to neurodegenerative* Correspondence: linda.vaneldik@uky.edu
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unless otherwise stated.complications. For example, TBI increases susceptibility
for development of Alzheimer’s disease (AD) and other
dementias, post-traumatic epilepsy, neuropsychiatric dis-
orders, post-traumatic stress disorder, and chronic trau-
matic encephalopathy. The diverse neurologic sequelae of
TBI can occur months, years, even decades after the last
head injury [2-4]. Thus, it is critical to elucidate the under-
lying pathophysiology by which an initial TBI elicits an
enhanced susceptibility to subsequent injuries and neuro-
logic complications.
A key mechanism that drives pathophysiology progression
in many CNS disorders involves abnormal inflammatorytral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cent reviews, see [5,6]). Studies with animal models and hu-
man head injury patients suggest that proinflammatory
cytokine overproduction is one component of the neuroin-
flammation that contributes to adverse outcomes following
TBI [7,8]. This raises the importance of exploring attenu-
ation of proinflammatory cytokine overproduction as a
therapeutic target.
We developed [9] a CNS-penetrant, small molecule ex-
perimental therapeutic, MW01-2-151WH (MW151), that
selectively restores injury- or disease-induced overproduc-
tion of proinflammatory cytokines towards homeostasis.
MW151 is efficacious in a variety of animal models of dis-
eases where proinflammatory cytokine overproduction is
a component of disease progression, including (1) animal
models of Alzheimer’s disease [9,10]; (2) neurologic seque-
lae of seizures [11,12]; (3) EAE model of multiple sclerosis
[13]; (4) a ‘two-hit’ injury model of increased susceptibility
to seizures after a TBI [14], and (5) radiation-induced cog-
nitive impairment [15]. Particularly relevant to the current
study, we have previously reported [16] that MW151 is ef-
ficacious in a closed head injury (CHI) model of diffuse
TBI in mice, when administered during the time of the
acute post-injury cytokine surge. The observation that
MW151 attenuates disease- and injury-induced proin-
flammatory cytokine overproduction and reduces down-
stream synaptic and cognitive dysfunction in multiple
animal models of CNS disorders suggests that further de-
velopment of MW151 is warranted.
A key component of developing proinflammatory cyto-
kine modulators for altering disease progression is consid-
eration of dosing. Dosing is the pharmacological basis of
therapeutic action and includes the amount of drug admin-
istered, the frequency of administration, and the time win-
dow during disease progression for administration. The
goal of this study was to probe the time window and con-
centration dependence of MW151 intervention to suppress
the targeted mechanism, proinflammatory cytokine up-
regulation, and the impact of appropriate dosing on efficacy
and attenuation of downstream cognitive dysfunction.Materials and methods
Animals
The Institutional Animal Care and Use Committee of the
University of Kentucky approved the use of animals in this
study, which were conducted in accordance with the prin-
ciples of animal care and experimentation in the Guide
for the Care and Use of Laboratory Animals. All experi-
ments used adult male C57BL/6 J mice obtained from
Jackson Laboratory. Animal experiments followed the re-
cent NIH guidelines for rigor in study design and analysis
[17,18], including randomization of animals and blinding
of treatment groups and tissue samples.Surgical procedure
Adult mice were subjected to a CHI using a stereotaxic
electromagnetic impactor [19]. Under continuous inhal-
ation of isoflurane (3.5%, 1 liter/min) anesthesia, with the
head stabilized using ear bars in a digital mouse stereo-
taxic frame (Stoelting Co., Wood Dale, USA), a midline
sagittal scalp incision was made. To displace the force of
the impact, a 1-ml latex pipette bulb (ThermoFisher Sci-
entific, Waltham, USA) was placed under the head and
filled with water. A 5.0-mm steel tip impounder (Leica
Biosytems, Wetzlar, Germany) was used to deliver a single
controlled midline cortical impact, delivered at coordi-
nates: ML = 0.0 mm; AP = −1.5 mm, with a controlled vel-
ocity (5.0 ± 0.2 m/s), dwell time (100 ms), and impact
depth (1.0 mm). Mice with depressed skull fracture or vis-
ible hemorrhage were excluded from the study. Sham-
injured mice underwent identical surgical procedures as
the trauma group, but no impact was delivered. The time
elapsed until the animal spontaneously rights was re-
corded as an acute neurological assessment, and defined
as the righting reflex time. In this mild diffuse injury
model, the mortality rate is <1%. Following each surgery,
animals were monitored continuously until they have fully
recovered.
Synthesis and use of MW151
MW01-2-151SRM (2-(4-(4-methyl-6-phenylpyridazin-3-
yl)piperazin-1-yl)pyrimidine) was synthesized and char-
acterized as previously reported [9]. As previously
described [10], MW151 was dissolved in 0.9% sterile
NaCl (saline: Hospira NDC 0409-4888-10), and adminis-
tered by intraperitoneal (i.p.) injection. Saline was
injected i.p. as the vehicle control.
Radial arm water maze behavior
A 2-day radial arm water maze (RAWM) protocol was used
as previously described [20]. Briefly, in block 1 (first 6 trials)
and block 2 (6 trials), mice were trained to identify the plat-
form location by alternating between a visible and a hidden
platform (3 hidden platform trials and 3 visible platform
trials for each block). Block 3 (3 trials) used only a hidden
platform. The next day, mice were tested in 3 blocks of 5
trials each (blocks 4 to 6; 15 total trials), all using only a
hidden platform to test their spatial memory retention.
EthoVision XT 8.0 video tracking software (Noldus Infor-
mation Technology, Wageningen, The Netherlands) was
used to record and score the behavior. Data are presented
as the average errors per block during the hidden platform
trials.
Brain tissue harvesting, biochemical, and
immunohistochemical endpoints
Mice were deeply anesthetized with 5% isoflurane prior to
transcardial perfusion with ice-cold PBS for 5 min, then
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ously described [10,21]. Cytokine and chemokine levels
were measured in brain homogenates using Meso Scale
Discovery (MSD) ELISA, as previously described [10,21].
Immunohistochemical (IHC) staining was done following
established methods, and quantified using the Aperio
ScanScope XT digital slidescanner and Aperio Image-
Scope software positive pixel count algorithm (version 9),
as previously described [10,21]. Primary antibodies used
included rabbit anti-glial fibrillary acidic protein (GFAP)
(Dako Cat#Z0334; (1:10,000); Dako, Glostrup, Denmark);
rabbit anti-IBA1 (Wako Cat#019-19741; (1:10,000); Wako
Chemicals USA Inc., Richmond, USA); and rat anti-CD45
(YW62.3) (ThermoFisher Scientific Cat#MA1447081;
(1:10,000); ThermoFisher Scientific, Waltham, USA).
Statistics
JMP software version 10.0 was used for statistical analysis.
A repeated measures ANOVA was used for RAWM. For
all other endpoints, a one-way ANOVA was used to
examine differences within those factors. A two-tailed Stu-
dent’s t test was used for post hoc analysis to compare only
the effect of injury compared to sham and to compare the
effect of MW151 compared to vehicle in the injured mice,
as these comparisons were determined a priori to be the
ones of interest. Differences between means were consid-
ered significant at α = 0.05. Graphs were generated using
GraphPad Prism software version 6.0, and values are
expressed as mean ± SEM, unless otherwise noted.
Results and discussion
Selection of preclinical model and validation of
mechanism of action
In the field of neurotrauma, a number of preclinical models
have been characterized (for review of rodent TBI protocols,
see [22]). Because no single animal model can reproduce the
complexity of TBI pathology seen in humans, it is important
to choose a model that has an injury with some relevance to
the clinical paradigm. Most important for pharmacological
studies, the model should exhibit changes in the targeted
pathways in order to test mechanistic pharmacodynamics,
or how drug intervention alters the mechanism of action.
For this study, we chose a midline CHI protocol that uses
an electromagnetic impactor and produces a diffuse brain
injury without focal brain lesions, fracture of the skull, or
hemorrhages. Mild diffuse injury after closed-skull impact is
similar to the injury characteristics observed most com-
monly in human head injury. In addition, this experimental
protocol produces a reproducible injury with low mortality,
making it technically feasible for pharmacological studies.
MW151 was developed [9] using the classic functional
approach with the focus on a deliverable with the following
desired pharmacological properties: selective suppression
of stressor-induced up-regulation of neuroinflammatoryresponses of activated glia such as proinflammatory cyto-
kine overproduction. An advantage of the functional ap-
proach is the unbiased focus on attenuation of pathology
progression, with potential for identification of alternative
therapeutic strategies, which has resulted in historical suc-
cess in delivering widely used drugs to clinical practice. Our
discovery process to develop novel small molecules began
with a validated mouse model [23-25] and discovery engine
that used novel molecule design based on pharmacoinfor-
matics and a curated database of CNS-penetrant drugs.
The starting point for the family of compounds encompass-
ing MW151 and its analogs was a chemical scaffold present
in previous clinically useful CNS drugs. The strict exclusion
criteria of the approach resulted in the synthesis and testing
of fewer than two dozen novel small molecules to find vi-
able hits. Focused medicinal chemistry refinement was then
done to improve metabolic stability and pharmacokinetic
features. MW151 was one of two best-in-class deliverables
from the discovery engine’s hierarchal pharmacological
screening process.
MW151 is a water-soluble, chemically stable, small
molecule (423 MW) that is orally bioavailable and CNS-
penetrant, with a brain:blood ratio >1, similar to other
CNS drugs in clinical use or under development.
MW151 is selective in its action and is not a pan-
suppressor of neuroinflammation. For example, MW151
suppresses disease- and injury-induced overproduction
of proinflammatory cytokines such as IL-1β and TNFα,
but does not block anti-inflammatory cytokines such as
IL-10 [10]. MW151’s pharmacological mechanism of ac-
tion is one that restores activated pathways back towards
homeostasis, as shown by its lack of effect in control
animals and its failure to depress basal cytokine levels at
efficacious doses. Further, efficacy is achieved in the ab-
sence of any signs of general immunosuppression or
non-selective anti-inflammatory action [9-16,26]. There-
fore, future development of MW151 could have broad
clinical applications for a number of other CNS disor-
ders where proinflammatory cytokine dysregulation is
part of the pathophysiology progression mechanism and
restoration towards homeostasis is the desired thera-
peutic goal.
A critical first step before testing MW151 in the
CHI model was to validate that the model exhibits an
injury-induced acute proinflammatory cytokine surge, the
mechanism of action targeted by MW151. Therefore, we
subjected mice to CHI and measured IL-1β levels in the
cortex at various post-injury (p.i.) time points. As shown
in Figure 1A, levels of IL-1β in the cortex began to rise at
3 h p.i., peaked at 9 h p.i., and returned to pre-injury levels
by 12 to 24 h p.i. This pattern of the acute cytokine surge
is similar to that found previously in a comparable CHI
model [16], although that CHI protocol resulted in a
slightly delayed peak IL-1β level (12 h). The reason for the
Figure 1 Time window for suppression of acute cytokine surge by MW151. (A) Temporal changes in IL-1β protein levels were measured in tissue
homogenates from the cortex of adult C57BL/6 J mice subjected to sham conditions (red line mean± SEM), or at select time points after the CHI (n= 4 per
group). (B) Treatment of mice with MW151 (5 mg/kg i.p.) at 3 and 6 h post-injury (p.i.) significantly reduced IL-1β up-regulation at 9 h p.i., compared to CHI +
saline vehicle (veh) control (n= 4 sham; n= 9 CHI + veh; n= 10 CHI +MW151). (C, D) Injured mice were treated with veh or MW151 (5 mg/kg i.p.) at 3 h and
6 h, at 3 h only, or at 6 h only, and cytokine and chemokine protein levels were measured in cortex homogenates at 9 h p.i. (n= 7 to 20 per group). (C)
Injury-induced IL-1β levels were significantly suppressed with MW151 regardless of time of treatment. (D) Heatmap of the relative changes in cytokine and
chemokine protein levels showing the specificity of MW151 for IL-1β and IL-6. Significance for a given inflammatory marker is indicated by *P< 0.05,
**P< 0.005, ***P< 0.001 compared to sham treated mice. ‡P< 0.05 compared to CHI + veh.
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but could reflect strain differences in the mice (C57BL/6 J
vs. CD-1), or minor variations in the CHI models. Previ-
ously, Lloyd et al. showed that administration of MW151
(5 mg/kg i.p.) at two post-injury time points when cyto-
kines were increasing (3 h and 9 h) significantly reduced
the peak (12 h p.i.) of the proinflammatory cytokine (that
is, IL-1β) surge in the CNS [16]. To confirm that MW151
administration in our midline CHI model would suppress
IL-1β, we injected MW151 (5 mg/kg i.p.) at two time
points (3 h and 6 h) during the acute rise in IL-1β, and
harvested brain tissue at the 9-h p.i. peak IL-1β time point.
As shown in Figure 1B, MW151 administered under this
treatment paradigm significantly reduced the IL-1β levels
in the cortex at 9 h p.i., demonstrating engagement of the
pharmacological mechanism of action by MW151.Intervention time window for suppression of acute
cytokine surge by MW151
After confirming that our CHI model showed the pre-
dicted acute cytokine surge and that two administrations
of MW151 suppressed this surge, we tested whether a sin-
gle injection of MW151 administered at different times
after injury would be effective at inhibiting IL-1β levels.
We tested intervention at two clinically relevant time win-
dows, 3 h or 6 h following CHI. MW151 (5 mg/kg i.p.)
was injected at either 3 or 6 h p.i., brain harvested at the
9-h p.i. time point, and IL-1β levels in cortex homogenates
determined. A positive control group that received two in-
jections of MW151 (at 3 and 6 h p.i.) was also included. In
the vehicle-treated groups (sham or CHI), there was no
difference in IL-1β levels in the groups treated at 3, 6, or 3
and 6 h p.i.; therefore, these vehicle treatment groups were
Table 1 Levels of cytokines and chemokines in the cortex at the 9-h p.i. time point
Treatment group IL-1β IL-6 IL-10 CCL2 CXCL1
sham + veh (n = 7) 4.9 ± 1.3 16.1 ± 10.8 1.3 ± 2.0 53.0 ± 7.6 103.8 ± 100.2
CHI + veh (n = 20) 9.8 ± 4.7 41.0 ± 39.1 7.2 ± 5.8 445.1 ± 240.4 274.0 ± 211.2
CHI + MW151 at 3 h and 6 h (n = 10) 7.0 ± 3.8 22.0 ± 13.7 6.5 ± 3.0 403.3 ± 134.5 235.6 ± 125.9
CHI + MW151 at 3 h (n = 10) 6.8 ± 2.5 21.4 ± 15.4 5.6 ± 4.6 393.5 ± 134.6 214.6 ± 132.1
CHI + MW151 at 6 h (n = 9) 6.8 ± 2.5 23.7 ± 21.7 6.9 ± 4.3 414.2 ± 134.5 246.9 ± 88.3
Data are expressed as pg/ml/mg (mean ± SD). CHI, closed head injury; veh, vehicle.
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(Figure 1C,D; Table 1). Strikingly, we found that MW151
(5 mg/kg) significantly reduced IL-1β levels almost to pre-
injury levels, not only when two injections were given (3
and 6 h), but even after a single administration at either 3
or 6 h p.i. (58%, 63%, and 61% decrease from CHI + veh,
respectively) (Figure 1C). MW151 administration also re-
duced IL-6 levels (Figure 1D), but the decrease did not
reach statistical significance. In addition, we found that
MW151 did not significantly reduce the levels of the anti-
inflammatory cytokine IL-10, or the chemokines CCL2 or
CXCL1 (Figure 1D). The lack of effect of MW151 on
CCL2 levels in our CHI model is in contrast to previous
findings [16] in a different CHI model, but the reason for
this difference was not explored further. Our data with
acute administration of MW151 demonstrate that the
injury-induced IL-1β levels are inhibited even when
MW151 is administered at 6 h p.i. and that the compound
shows selectivity for IL-1β and IL-6 compared to the other
markers measured.
Concentration dependence of MW151 inhibition of
post-injury IL-1β up-regulation
To determine whether MW151 showed dose-dependent
suppression of IL-1β in the CNS following a CHI, we tested
three different doses of MW151 (1, 5, and 10 mg/kg)Figure 2 Dose-dependent suppression of IL-1β up-regulation by MW1
p.i. with saline vehicle (veh). CHI mice were injected i.p. at 6 h p.i. with MW
1β (A) and CCL2 (B) protein were measured in cortex homogenates at the
< 0.05, ‡‡P < 0.01 CHI + veh compared to CHI + MW151 (n = 10 sham + vehadministered at a single time (6 h p.i.). Brain tissue was har-
vested at 9 h p.i., and levels of IL-1β and CCL2 in the
cortex were measured, to assess the target mechanism of
inhibiting proinflammatory cytokine overproduction (IL-
1β) and to assess the selectivity of MW151 by determining
if it would suppress CCL2 levels at higher doses. As shown
in Figure 2, MW151 showed dose-dependent suppression
of IL-1β up-regulation, with significant inhibition at doses
of 5 and 10 mg/kg. MW151 had no effect on injury-
induced CCL2 levels at any dose tested.
Functional efficacy of MW151 to suppress CHI-induced
cognitive impairment
We tested the potential of MW151 to suppress injury-
induced cognitive deficits in two different treatment
paradigms (Figure 3A). In the first paradigm, MW151
(5 mg/kg) was administered at 3 and 6 h p.i., and then
once daily for 7 days. This extended treatment approach
uses a similar dosing paradigm to a previous report
showing that a structural analog of MW151 can rescue
TBI-induced cognitive impairments [27]. In the second
paradigm, a single dose of MW151 (5 mg/kg) was given at
the 6-h p.i. time point. In both treatment paradigms, mice
were tested starting at day 14 p.i. for cognitive impairment
in the RAWM. The rationale for this experimental design
was to test if suppression of the peak IL-1β response with51. Mice were subjected to sham injury or CHI, and injected i.p. at 6 h
151 at one of three different doses (1, 5, and 10 mg/kg). Levels of IL-
9-h p.i. time point. *P < 0.05, ***P < 0.001 compared to sham mice. ‡P
; n = 20 CHI + veh; n = 9 to 10 CHI + MW151).
Figure 3 Functional efficacy of MW151 to suppress CHI-induced cognitive impairment. (A) Overview of study design. MW151 (5 mg/kg i.p.) was
administered either as a single acute treatment at 6 h p.i. or in a more extended treatment paradigm (3 h, 6 h, then once daily for 7 days p.i.). (B) Mice were
tested for cognitive deficits in the RAWM starting at 14 days p.i. (n= 23 sham; n= 27 CHI + veh; n= 12 CHI +MW150 acute; n= 14 CHI +MW150 chronic).
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be sufficient to prevent subsequent cognitive impairment
assessed 2 weeks later or if a more extended treatment
was required.
As shown in Figure 3B, the CHI mice treated with ve-
hicle showed a significant impairment in RAWM com-
pared to the sham group. MW151 administered underthe extended treatment paradigm (3 h, 6 h, and 1 to
7 days p.i.) led to a significant improvement in RAWM
performance. However, a single injection of MW151 at
6 h p.i. did not reduce the CHI-induced cognitive im-
pairment in the RAWM assessed 2 weeks later. There
are several possible interpretations of these results. It is
possible that a single 6-h p.i. administration of MW151,
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sponse, may be too late to inhibit other key proinflam-
matory cytokines that show an earlier post-injury surge
and that may contribute to subsequent impairment. It is
also possible that other detrimental neuroinflammatory
responses that contribute to cognitive impairment occur
during the first 7 days p.i. and that administration of
MW151 during this time window inhibits those re-
sponses. Finally, it is possible that a single administration
of MW151 is not sufficient to prevent cognitive deficits
but that functional efficacy requires a more prolonged
administration of drug. Future studies exploring the
therapeutic efficacy window in more detail will be re-
quired to address these possibilities.
Effects of MW151 on glia morphological changes
To determine what effect, if any, MW151 had on micro-
glia and astrocyte morphological activation, we mea-
sured IBA1, CD45, and GFAP immunohistochemistry.
Using the Aperio ScanScope digital slide scanner andFigure 4 Effects of MW151 treatment on glia morphological activation.M
injured mice were administered MW151 (5 mg/kg i.p.) at 3 h, 6 h, and once daily
for microglia (IBA1, CD45) and astrocyte (GFAP) morphological activation. (A) Ove
analysis of glia activation using the Aperio ScanScope. Heatmap shows the effect
GFAP (D) IHC. Treatment with MW151 reduced IBA1, CD45, and GFAP staining in
on glial staining in other areas of the brain. **P<0.005 compared to sham mice.
and GFAP (G) in the focus region of the neocortex show the robust glial morphoimage software, we identified five brain regions of interest
(ROI), which were outlined as illustrated in Figure 4A.
Quantification of the digital slide was done using the posi-
tive pixel algorithm for the five ROIs. As shown by the
heatmap in Figure 4B,C,D, the largest increase in glial acti-
vation in the CHI mice compared to the sham mice was
in the neocortex most proximal to the point of impact.
The focus region of the neocortex, defined by an area that
extended laterally from midline by 1.75 cm, showed a
large increase in staining for all three markers (Figure 4E,
F,G). In addition to the focus region, there were injury-
induced increases in staining in the entire neocortex
(which included the focus regions), in the entorhinal
cortex, and in the corpus callosum, but not in the hippo-
campus (see Table 2). Treatment with MW151 in the ex-
tended treatment paradigm (3 h, 6 h, and 1 to 7 days p.i.)
reduced IBA1, CD45, and GFAP staining in the focus
region of the cortex. There was little effect of MW151
treatment on glial staining in other areas of the brain.
These IHC results cannot be directly compared to ourice were subjected to sham injury or CHI and administered veh control;
for 7 days p.i.. Brain tissue was prepared for IHC at 16 days p.i. and stained
rview of regions of interest (ROIs) used for quantitative neuropathological
of injury and MW151 treatment in five ROIs for IBA1 (B), CD45 (C), and
the focus region of the cortex. There was little effect of MW151 treatment
See also Table 2. Representative photomicrographs of IBA1 (E), CD45 (F),
logical activation that occurs in response to the injury.
Table 2 Effect of CHI and MW151 treatment on IBA1,
CD45, and GFAP staining
IHC
stain
Brain region Sham+ veh CHI + veh CHI +MW151
(n = 11) (n = 14) (n = 14)
IBA1 Neocortex: focus 0.0 ± 0.2 0.3 ± 0.5 0.2 ± 0.3
Neocortex: all 0.0 ± 0.1 0.1 ± 0.2 0.0 ± 0.2
Hippocampus 0.0 ± 0.2 0 ± 0.2 −0.1 ± 0.1
Corpus callosum 0.0 ± 0.5 0.1 ± 0.5 0.1 ± 0.5
Entorhinal cortex 0.0 ± 0.2 0 ± 0.2 0.0 ± 0.2
CD45 Neocortex: focus 0.0 ± 1.3 7.7 ± 10.4 4.4 ± 5.2
Neocortex: all 0.0 ± 1.2 2.3 ± 3.6 1.4 ± 2.5
Hippocampus 0.0 ± 0.7 0.2 ± 0.9 0.3 ± 1.1
Corpus callosum 0.0 ± 0.6 1.2 ± 1.1 1.3 ± 1.3
Entorhinal cortex 0.0 ± 0.7 0.6 ± 1.0 0.9 ± 1.5
GFAP Neocortex: focus 0.0 ± 0.3 4.6 ± 3.7 3.9 ± 3.1
Neocortex: all 0.0 ± 0.2 1.7 ± 1.4 1.5 ± 1.3
Hippocampus 0.0 ± 0.1 0.0 ± 0.1 0.0 ± 0.1
Corpus callosum 0.0 ± 0.2 0.3 ± 0.3 0.4 ± 0.3
Entorhinal cortex 0.0 ± 0.2 0.4 ± 0.3 0.4 ± 0.3
Data expressed as change from sham + veh baseline (mean ± SD). CHI, closed
head injury; IHC, immunohistochemical; GFAP, glial fibrillary acidic protein;
veh, vehicle.
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digm and experimental protocols were used. However, the
overall finding that repeat dosing with MW151 during the
pathophysiology progression time window can alter glia
IHC is consistent across studies.
Conclusions
Our goal is to develop safe and effective therapeutics
that alter the pathological progression of TBI by redu-
cing the potential for destructive glia inflammation/
neuron dysfunction cycles and their long-term cognitive
effects. Consistent with this, MW151 has a documented
disease-modifying efficacy in diverse animal models in
which cognitive dysfunction is brought about by injury-
or disease-induced overproduction of proinflammatory
cytokines [9-16,26]. The results presented here extend
the potential clinical utility of MW151 in CHI by docu-
menting efficacy in a standard preclinical model of
diffuse TBI. Exploration of dosing revealed that MW151
exerts its pharmacological mechanism of action at low con-
centrations even when administered up to 6 h following
CHI. In addition, repeat administration of MW151 during
the first 7 days after injury reduced the glial activation and
cognitive impairment seen at 14 days after injury. Overall,
the extended pharmacodynamics effect when MW151
intervention is performed during post-injury proinflamma-
tory cytokine up-regulation is consistent with MW151
pharmacological mechanism of action and indicates the po-
tential for efficacious use of MW151 administration up toseveral hours after injury. These results suggest that a
therapeutic strategy targeting neuroinflammatory responses
following TBI, such as with MW151, may have potential to
be translated into improved clinical outcomes in human
head injury.
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